LT3080103T - Biarilo junginiai, tinkami panaudoti žmogaus ligų gydymui onkologijoje, neurologijoje ir imunologijoje - Google Patents

Biarilo junginiai, tinkami panaudoti žmogaus ligų gydymui onkologijoje, neurologijoje ir imunologijoje

Info

Publication number
LT3080103T
LT3080103T LTEP14825001.2T LT14825001T LT3080103T LT 3080103 T LT3080103 T LT 3080103T LT 14825001 T LT14825001 T LT 14825001T LT 3080103 T LT3080103 T LT 3080103T
Authority
LT
Lithuania
Prior art keywords
neurology
oncology
immunology
treatment
compounds useful
Prior art date
Application number
LTEP14825001.2T
Other languages
English (en)
Lithuanian (lt)
Inventor
Brian Hopkins
Bin Ma
Timothy Chan
Lihong Sun
Lei Zhang
Gnanasambandam Kumaravel
Joseph Lyssikatos
Kevin Koch
Hua Miao
Original Assignee
Biogen Ma Inc.
Sunesis Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc., Sunesis Pharmaceuticals, Inc. filed Critical Biogen Ma Inc.
Publication of LT3080103T publication Critical patent/LT3080103T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
LTEP14825001.2T 2013-12-11 2014-12-11 Biarilo junginiai, tinkami panaudoti žmogaus ligų gydymui onkologijoje, neurologijoje ir imunologijoje LT3080103T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361914886P 2013-12-11 2013-12-11
PCT/US2014/069853 WO2015089337A1 (en) 2013-12-11 2014-12-11 Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology

Publications (1)

Publication Number Publication Date
LT3080103T true LT3080103T (lt) 2018-08-10

Family

ID=52302344

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP14825001.2T LT3080103T (lt) 2013-12-11 2014-12-11 Biarilo junginiai, tinkami panaudoti žmogaus ligų gydymui onkologijoje, neurologijoje ir imunologijoje

Country Status (32)

Country Link
US (4) US9809577B2 (enExample)
EP (3) EP3872075A1 (enExample)
JP (4) JP6431914B2 (enExample)
KR (1) KR102413253B1 (enExample)
CN (3) CN106459002B (enExample)
AR (2) AR098721A1 (enExample)
AU (2) AU2014362231B2 (enExample)
BR (1) BR112016012860A2 (enExample)
CA (1) CA2932608C (enExample)
CL (2) CL2016001435A1 (enExample)
CY (1) CY1120517T1 (enExample)
DK (1) DK3080103T3 (enExample)
EA (2) EA037942B1 (enExample)
ES (1) ES2678021T3 (enExample)
HR (1) HRP20181109T1 (enExample)
HU (1) HUE040346T2 (enExample)
IL (2) IL246031B (enExample)
LT (1) LT3080103T (enExample)
MX (2) MX370103B (enExample)
MY (1) MY179781A (enExample)
NZ (1) NZ721217A (enExample)
PH (1) PH12016501107B1 (enExample)
PL (1) PL3080103T3 (enExample)
PT (1) PT3080103T (enExample)
RS (1) RS57662B1 (enExample)
SA (1) SA518391170B1 (enExample)
SG (2) SG10201908558WA (enExample)
SI (1) SI3080103T1 (enExample)
SM (1) SMT201800373T1 (enExample)
TW (3) TWI675833B (enExample)
WO (1) WO2015089337A1 (enExample)
ZA (1) ZA201706244B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE043522T2 (hu) * 2009-09-04 2019-08-28 Biogen Ma Inc Bruton tirozinkináz inhibitorok
AR091273A1 (es) 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
KR102413253B1 (ko) * 2013-12-11 2022-06-27 바이오젠 엠에이 인코포레이티드 종양, 신경 및 면역에서 인간 질환을 치료하는데 유용한 바이아릴 화합물
US20180282310A1 (en) 2015-06-10 2018-10-04 Biogen Ma Inc. Forms and compositions of biaryl inhibitors of bruton's tyrosine kinase
US20180179189A1 (en) * 2015-06-10 2018-06-28 Biogen Ma Inc. Adipate forms and compositions of biaryl inhibitors of bruton's tyrosine kinase
AU2016368257C1 (en) * 2015-12-07 2019-12-05 Suzhou Sinovent Pharmaceuticals Co., Ltd. Five-membered heterocyclic amides wnt pathway inhibitor
JO3794B1 (ar) * 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
JO3793B1 (ar) * 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv مثبطات تيروزين كاينيز بروتون وأساليب استخدامها
CN118147079A (zh) * 2016-03-31 2024-06-07 来恩生物医药私人有限公司 表达外源病毒特异性t细胞受体(tcr)的非活化t细胞
EP3476848A4 (en) * 2016-06-27 2020-01-15 Hangzhou Rex Pharmaceutical Co., Ltd BENZOFURANE-PYRAZOLE-AMINE PROTEIN KINASE INHIBITOR
EP3487852A1 (en) 2016-07-21 2019-05-29 Biogen MA Inc. Succinate forms and compositions of bruton's tyrosine kinase inhibitors
JP7076741B2 (ja) 2016-12-27 2022-05-30 国立研究開発法人理化学研究所 Ｂｍｐシグナル阻害化合物
JOP20190233A1 (ar) 2017-04-14 2019-10-02 Biogen Ma Inc نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون
CN112262137A (zh) 2018-01-10 2021-01-22 阿林齐生物制药公司 四氢异喹啉化合物
TWI835770B (zh) 2018-01-19 2024-03-21 美商胞質動力學公司 心肌節抑制劑
US20190330226A1 (en) * 2018-04-26 2019-10-31 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m1
US10899753B2 (en) 2018-05-14 2021-01-26 Biogen Ma Inc. Inhibiting agents for Bruton's tyrosine kinase
US12187712B2 (en) 2018-06-26 2025-01-07 Cytokinetics, Inc. Cardiac sarcomere inhibitors
JP7438148B2 (ja) 2018-06-26 2024-02-26 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤
CA3224985A1 (en) 2018-07-31 2020-02-06 Loxo Oncology, Inc. Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide
JP7476214B2 (ja) * 2018-10-15 2024-04-30 バイオジェン・エムエイ・インコーポレイテッド ブルトン型チロシンキナーゼ阻害剤の結晶多形
WO2020118683A1 (en) * 2018-12-14 2020-06-18 Lynk Pharmaceuticals Co. Ltd. Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof
JP7747523B2 (ja) * 2019-05-15 2025-10-01 バイオジェン・エムエイ・インコーポレイテッド ブルトン型チロシンキナーゼの阻害剤
CN110627775A (zh) * 2019-10-24 2019-12-31 嘉兴特科罗生物科技有限公司 一种小分子化合物
US20230121818A1 (en) * 2019-12-23 2023-04-20 Biogen Ma Inc. Btk inhibitors
CN116917279A (zh) * 2020-08-07 2023-10-20 渤健马萨诸塞州股份有限公司 Btk抑制剂
UY39370A (es) * 2020-08-07 2022-02-25 Biogen Ma Inc Inhibidores de la btk
EP4313023A1 (en) 2021-04-02 2024-02-07 Biogen MA Inc. Combination treatment methods of multiple sclerosis
TW202317558A (zh) * 2021-06-21 2023-05-01 英屬開曼群島商百濟神州有限公司 （ｒ）－戊二醯亞胺ｃｒｂｎ配位體及使用方法
AU2022424178A1 (en) * 2021-12-30 2024-07-11 Beone Medicines I Gmbh Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use
CN116891437B (zh) * 2022-04-06 2025-10-28 长春金赛药业有限责任公司 氨基酸衍生物、药物组合物及其制备方法和应用
WO2024146923A1 (en) 2023-01-04 2024-07-11 Ab Science Tubulin polymerization inhibitors
CN117088851A (zh) * 2023-07-13 2023-11-21 特科罗生物科技(成都)有限公司 一种嘧啶胺类nuak抑制剂及其制备方法和用途

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US833429A (en) * 1902-07-31 1906-10-16 Anthony Van Wagenen Automatic system of intercommunication.
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
DE69212850T2 (de) 1991-01-15 1997-03-06 Alcon Lab Inc Verwendung von Karrageenan in topischen ophthalmologischen Zusammensetzungen
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
GB9924862D0 (en) * 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds
MXPA03001226A (es) * 2000-08-08 2004-09-10 Johnson & Johnson Derivados de 4-pirimidinamina, composiciones farmaceuticas y metodos relacionados.
US20050014753A1 (en) 2003-04-04 2005-01-20 Irm Llc Novel compounds and compositions as protein kinase inhibitors
GB0325031D0 (en) * 2003-10-27 2003-12-03 Novartis Ag Organic compounds
EP1713775A4 (en) * 2004-01-30 2009-08-12 Smithkline Beecham Corp CHEMICAL COMPOUNDS
US20060178388A1 (en) * 2005-02-04 2006-08-10 Wrobleski Stephen T Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
DK1951684T3 (en) * 2005-11-01 2016-10-24 Targegen Inc BIARYLMETAPYRIMIDIN kinase inhibitors
UA109411C2 (uk) * 2005-11-01 2015-08-25 N-трет-бутил-3-(2-хлор-5-метилпіримідин-4-іламіно)бензолсульфонамід та його застосування в способі одержання сполуки
WO2007089768A2 (en) 2006-01-30 2007-08-09 Exelixis, Inc. 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as jak-2 modulators and pharmaceutical compositions containing them
AR063946A1 (es) * 2006-09-11 2009-03-04 Cgi Pharmaceuticals Inc Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
CA2668338A1 (en) * 2006-11-01 2008-05-08 Chroma Therapeutics Ltd. Ikk-.beta. serine-threonine protein kinase inhibitors
CN101730699A (zh) * 2007-03-21 2010-06-09 百时美施贵宝公司 可用于治疗增殖性、变应性、自身免疫性和炎症性疾病的稠合杂环化合物
US8809273B2 (en) * 2007-03-28 2014-08-19 Pharmacyclics, Inc. Inhibitors of Bruton's tyrosine kinase
KR20160116045A (ko) * 2007-10-05 2016-10-06 베라스템, 인코포레이티드 피리미딘 치환된 퓨린 유도체
JP5743897B2 (ja) * 2008-11-20 2015-07-01 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ 化合物
US9029359B2 (en) * 2009-09-04 2015-05-12 Biogen Idec Ma, Inc. Heteroaryl Btk inhibitors
HUE043522T2 (hu) * 2009-09-04 2019-08-28 Biogen Ma Inc Bruton tirozinkináz inhibitorok
US8334292B1 (en) * 2010-06-14 2012-12-18 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimidine compounds and methods of making and using same
JP2014500254A (ja) 2010-11-09 2014-01-09 セルゾーム リミティッド Ｔｙｋ２阻害剤としてのピリジン化合物およびそのアザ類似体
EP2548622B1 (en) 2011-03-31 2015-06-17 Mizuno Corporation Iron golf club head and iron golf club
CA2832919A1 (en) 2011-04-12 2012-10-18 Ryan C. Holcomb Compounds, compositions, and therapeutic uses thereof
AR091273A1 (es) * 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
KR102413253B1 (ko) 2013-12-11 2022-06-27 바이오젠 엠에이 인코포레이티드 종양, 신경 및 면역에서 인간 질환을 치료하는데 유용한 바이아릴 화합물
EP3080122B1 (en) 2013-12-11 2018-10-31 Biogen MA Inc. Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
AU2015268962A1 (en) * 2014-06-04 2017-01-12 Thomas Helledays Stiftelse For Medicinsk Forskning MTH1 inhibitors for treatment of inflammatory and autoimmune conditions
ES2907622T3 (es) * 2014-10-06 2022-04-25 Merck Patent Gmbh Compuestos de heteroarilo como inhibidores de BTK y usos de estos
US20180282310A1 (en) 2015-06-10 2018-10-04 Biogen Ma Inc. Forms and compositions of biaryl inhibitors of bruton's tyrosine kinase
JOP20190233A1 (ar) 2017-04-14 2019-10-02 Biogen Ma Inc نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون

Also Published As

Publication number Publication date
MX2016007611A (es) 2016-09-09
AU2014362231A1 (en) 2016-07-07
HRP20181109T1 (hr) 2018-11-02
EA201792348A1 (ru) 2018-09-28
CA2932608C (en) 2023-02-14
ZA201706244B (en) 2019-04-24
PT3080103T (pt) 2018-07-23
EA201691114A1 (ru) 2016-11-30
MX2019014228A (es) 2020-01-23
AR098721A1 (es) 2016-06-08
US20220332705A1 (en) 2022-10-20
US10081619B2 (en) 2018-09-25
TWI675833B (zh) 2019-11-01
EA037942B1 (ru) 2021-06-10
AU2014362231B2 (en) 2019-04-04
US20180093973A1 (en) 2018-04-05
JP6526167B2 (ja) 2019-06-05
SI3080103T1 (sl) 2018-11-30
SMT201800373T1 (it) 2018-09-13
WO2015089337A1 (en) 2015-06-18
IL246031B (en) 2019-10-31
EP3872075A1 (en) 2021-09-01
EA030538B1 (ru) 2018-08-31
JP2019163280A (ja) 2019-09-26
AR110381A2 (es) 2019-03-20
CN109096274A (zh) 2018-12-28
PL3080103T3 (pl) 2018-10-31
CY1120517T1 (el) 2019-07-10
CN106459002B (zh) 2018-08-21
TWI608002B (zh) 2017-12-11
US20190218204A1 (en) 2019-07-18
IL246031A0 (en) 2016-08-02
SA518391170B1 (ar) 2022-08-25
JP7076022B2 (ja) 2022-05-26
ES2678021T3 (es) 2018-08-08
MX388978B (es) 2025-03-20
RS57662B1 (sr) 2018-11-30
PH12016501107B1 (en) 2021-07-21
SG10201908558WA (en) 2019-10-30
JP2016539996A (ja) 2016-12-22
US9809577B2 (en) 2017-11-07
NZ721217A (en) 2021-12-24
EP3080103B9 (en) 2018-09-19
US10759783B2 (en) 2020-09-01
AU2019201997C1 (en) 2021-03-18
CN108947913A (zh) 2018-12-07
SG11201604595VA (en) 2016-07-28
TWI744672B (zh) 2021-11-01
CL2016001435A1 (es) 2017-06-09
KR20160106072A (ko) 2016-09-09
EP3080103B1 (en) 2018-04-18
AU2019201997A1 (en) 2019-04-18
BR112016012860A2 (pt) 2017-08-08
CA2932608A1 (en) 2015-06-18
CN109096274B (zh) 2022-07-01
HUE040346T2 (hu) 2019-03-28
TW201536765A (zh) 2015-10-01
EP3357921A2 (en) 2018-08-08
JP2018035201A (ja) 2018-03-08
AU2019201997B2 (en) 2020-09-17
CN106459002A (zh) 2017-02-22
EP3080103A1 (en) 2016-10-19
IL269569B (en) 2021-03-25
EP3357921A3 (en) 2018-09-12
TW202017931A (zh) 2020-05-16
KR102413253B1 (ko) 2022-06-27
US20160311802A1 (en) 2016-10-27
JP2021091733A (ja) 2021-06-17
DK3080103T3 (en) 2018-07-30
IL269569A (en) 2019-11-28
US11572356B2 (en) 2023-02-07
MY179781A (en) 2020-11-13
PH12016501107A1 (en) 2016-07-11
CL2017001459A1 (es) 2018-03-23
MX370103B (es) 2019-12-02
JP6431914B2 (ja) 2018-11-28
TW201811772A (zh) 2018-04-01

Similar Documents

Publication Publication Date Title
IL269569B (en) Biaryl compounds used in the treatment of human diseases in oncology, neurology and immunology
GB201320729D0 (en) Therapeutic compounds and their use
EP2991600A4 (en) MICRO-CLOSURES AND ASSOCIATED METHODS FOR TREATING SKIN
EP2967744A4 (en) SKIN TREATMENT DEVICE
GB201403093D0 (en) Therapeutic compounds and their use
EP2994078A4 (en) COMPRESSIVE PATIENT-HEATING DEVICE
EP2952149A4 (en) THERAPEUTIC TREATMENT DEVICE
GB201311361D0 (en) Compounds and their therapeutic use
ZA201802256B (en) Compounds and therapeutic uses thereof
PT3071247T (pt) Dispositivo para a construção de pele
IL247325A0 (en) Therapeutic methods using noribogaine and related compounds
ZA201607581B (en) Dosage forms and therapeutic uses l-4lchlorokynurenine
SI3016977T1 (sl) Humana protitelesa proti IL-32
GB201308736D0 (en) Compounds and their therapeutic use
GB201304038D0 (en) Treated cells and therapeutic uses
GB201316521D0 (en) Therapeutic apparatus
IL257737B (en) Medical compounds based on methanopyrrolo-pyridine-carboxylate and their synthesis
GB201410954D0 (en) Skin treatment devices and methods
GB201309498D0 (en) Novel diagnosis and therapy
IL241412A0 (en) Skin care device
IL240303B (en) Skin care device
GB201317804D0 (en) Therapeutic compounds and their use
GB201316173D0 (en) Compounds and their therapeutic use
GB201307677D0 (en) Compounds and their therapeutic use
GB201302884D0 (en) Novel methods for diagnosis and therapy